GlassScriptPhysician profile
Richard Goodman
NPI 1023073962
$3,588.36
in general payments reported to CMS, 2019-2025
19 companies · $88.37 in 2025
The $88.37 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $402 · 2021: $1,039 · 2022: $897 · 2023: $715 · 2024: $16.82 · 2025: $88.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,065.37 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $852.67 | 2019-2024 | Dovato, Cabenuva, Rukobia |
| Insmed, INC. | $496.16 | 2019-2023 | Arikayce |
| Merck Sharp & Dohme LLC | $278.25 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Janssen Biotech, INC. | $179.11 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $106.16 | 2020-2023 | Trogarzo, Egrifta |
| Melinta Therapeutics, LLC | $104.93 | 2019-2023 | Kimyrsa, Vabomere, Orbactiv |
| Pfizer INC. | $91.20 | 2022-2023 | |
| Paratek Pharmaceuticals, INC. | $80.40 | 2019-2023 | Nuzyra |
| Abbvie INC. | $57.04 | 2021-2023 | |
| Astellas Pharma US INC | $56.93 | 2021-2023 | Cresemba |
| Mayne Pharma Commercial LLC | $53.55 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $30.89 | 2023 | Symtuza |
| Dynavax Technologies Corporation | $27.88 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $25.26 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $24.15 | 2023 | Jakafi |
| Nabriva Therapeutics, Plc | $23.35 | 2022 | |
| La Jolla Pharmaceutical Company | $18.74 | 2023 | Xerava |
| Jazz Pharmaceuticals INC. | $16.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.